Zoetis Inc. (NYSE:ZTS) Shares Sold by Stonehage Fleming Financial Services Holdings Ltd

Stonehage Fleming Financial Services Holdings Ltd trimmed its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 33.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 688,758 shares of the company's stock after selling 352,382 shares during the period. Zoetis makes up about 3.1% of Stonehage Fleming Financial Services Holdings Ltd's portfolio, making the stock its 16th biggest position. Stonehage Fleming Financial Services Holdings Ltd owned about 0.15% of Zoetis worth $112,219,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in ZTS. Mizuho Securities USA LLC increased its holdings in shares of Zoetis by 13,726.9% during the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company's stock valued at $950,524,000 after purchasing an additional 4,829,815 shares in the last quarter. International Assets Investment Management LLC increased its holdings in Zoetis by 41,235.7% in the 3rd quarter. International Assets Investment Management LLC now owns 939,974 shares of the company's stock worth $183,652,000 after acquiring an additional 937,700 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in Zoetis by 296.9% in the 4th quarter. Assenagon Asset Management S.A. now owns 889,444 shares of the company's stock worth $144,917,000 after acquiring an additional 665,331 shares in the last quarter. Nordea Investment Management AB increased its holdings in Zoetis by 38.3% in the 4th quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company's stock worth $336,266,000 after acquiring an additional 572,511 shares in the last quarter. Finally, Holocene Advisors LP purchased a new stake in Zoetis in the 3rd quarter worth $110,809,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Trading Up 2.6 %

Shares of ZTS stock traded up $4.46 on Monday, hitting $173.07. 2,404,493 shares of the stock traded hands, compared to its average volume of 2,816,289. The firm's 50-day moving average price is $170.10 and its two-hundred day moving average price is $179.75. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The stock has a market capitalization of $78.08 billion, a PE ratio of 32.53, a PEG ratio of 2.57 and a beta of 0.89. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.53.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating analysts' consensus estimates of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The company had revenue of $2.40 billion for the quarter, compared to analysts' expectations of $2.29 billion. During the same quarter in the prior year, the company posted $1.36 earnings per share. Zoetis's revenue for the quarter was up 11.6% compared to the same quarter last year. As a group, analysts anticipate that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be given a $0.50 dividend. The ex-dividend date of this dividend is Tuesday, January 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.16%. This is a boost from Zoetis's previous quarterly dividend of $0.43. Zoetis's dividend payout ratio is presently 37.59%.

Analyst Ratings Changes

ZTS has been the subject of several recent analyst reports. Stifel Nicolaus cut their price target on shares of Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a report on Tuesday, January 7th. Leerink Partnrs raised shares of Zoetis to a "strong-buy" rating in a report on Monday, December 2nd. Leerink Partners initiated coverage on shares of Zoetis in a report on Monday, December 2nd. They issued an "outperform" rating and a $215.00 price target for the company. JPMorgan Chase & Co. boosted their price target on shares of Zoetis from $225.00 to $230.00 and gave the stock an "overweight" rating in a report on Friday, October 11th. Finally, UBS Group initiated coverage on shares of Zoetis in a report on Monday, December 9th. They set a "neutral" rating and a $196.00 target price for the company. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $211.89.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.